EU's CHMP positive on Novartis's ceritinib
This article was originally published in Scrip
The EU's CHMP has granted a positive opinion for Novartis's Zykadia (ceritinib) to treat adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib (Pfizer's Xalkori), making it set to be the first specifically approved treatment option for this population.
You may also be interested in...
NICE – the HTA body for England and Wales – has recommended that Novartis's Zykadia (ceritinib) be available on the NHS, but only at a discount. Novartis tells Scrip that with the imminent arrival of the UK's new Cancer Drugs Fund (CDF), there are concerns that access to new cancer drugs will become even more difficult.
Scrip caught up with Olema CEO Sean Bohen ahead of a crucial combination data readout due this month for its novel SERD, palazestrant, which it hopes will put the drug on the path to a $10bn-plus breast cancer market.
A sea of troubles continues for the German conglomerate as a Phase III failure for one of its future blockbuster hopes sends shares diving. Flickers of hope remain for the product in stroke.